Status:
UNKNOWN
The New Strategy for Pharmacological Treatment in People With Schizophrenia
Lead Sponsor:
Inje University
Conditions:
Schizophrenia
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.
Detailed Description
It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces lon...
Eligibility Criteria
Inclusion
- Schizophrenia, DSM-IV
- Acute phase
Exclusion
- Refractory Schizophrenia
- Substance Abuse
- High risk for suicide
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00352339
Start Date
August 1 2006
End Date
December 1 2010
Last Update
August 6 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongrae Hospital
Busan, South Korea, 609-370
2
Dongseo Hospital
Masan, South Korea, 630-856